Anavex life sciences reports fiscal 2023 second quarter financial results

Newly available preliminary efficacy results of surrogate biomarkers from the anavex®2-73-ad-004 study; allowing initiation of discussions with regulatory agencies for accelerated approval pathway for anavex®2-73 (blarcamesine) in alzheimer's disease with convenient oral treatment
AVXL Ratings Summary
AVXL Quant Ranking